Vertex Pharma rises after rival genetic disorder drug setback
10/08/2026 13:36
BUZZ-Vertex Pharma rises after rival genetic disorder drug setback ** Shares of drugmaker Vertex Pharmaceuticals VRTX.O climb 7.65% to $534 premarket
** Sionna Therapeutics SION.O says it will discontinue development of SION-719 experimental cystic fibrosis drug after it failed to meet main goal in a mid-stage trial
** Investors have been concerned Sionna can pose threat to VRTX's core cystic fibrosis business, but the trial failure is a clearing event - RBC Capital Markets
** VRTX markets Trikafta and Alyftrek for cystic fibrosis — a rare, chronic and life-shortening genetic disease which causes progressive lung damage
** Up to last close, stock up ~9.5% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria